SILVER SPRING
Hympavzi indication expanded for hemophilia A and B
- Sponsor
- Pfizer Inc. $PFE
- Drug
- Hympavzi · marstacimab-hncq
- Indication
- hemophilia A and B
FDA approved Pfizer's Hympavzi for additional hemophilia A and B patient populations based on significant medical need.
What this means
Hympavzi is an antibody drug that helps blood clot by blocking a natural protein that slows clotting, offering an alternative to traditional factor-replacement therapies for hemophilia. The FDA today expanded its approval to cover both hemophilia A and B patients, adding hemophilia B to its original clearance for hemophilia A. This gives more patients access to a weekly injection that may reduce bleeding episodes without needing frequent factor infusions.
Drug Watch — recent news on Hympavzi
- BASIS KIDS Phase 3 Trial Releases Encouraging Interim Data on Marstacimab for Hemophilia A, B - Docwire News
- Scientists screened thousands of molecules to develop Hympavzi - Hemophilia News Today
- Why Pfizer’s HYMPAVZI quietly widens options for people with hemophilia - AD HOC NEWS
- FDA Widens Access to Marstacimab-hncq for Hemophilia A and B - Hematology Advisor
- PFE gets FDA nod for expanded use of hemophilia drug Hympavzi - MSN
Sponsor Watch — recent news on Pfizer Inc.
- Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?
- The Real Question Buried Inside Merck Stock's Premium Price
- Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
- Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever
- Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances